GB0504767D0 - Lipocalin protein - Google Patents

Lipocalin protein

Info

Publication number
GB0504767D0
GB0504767D0 GBGB0504767.5A GB0504767A GB0504767D0 GB 0504767 D0 GB0504767 D0 GB 0504767D0 GB 0504767 A GB0504767 A GB 0504767A GB 0504767 D0 GB0504767 D0 GB 0504767D0
Authority
GB
United Kingdom
Prior art keywords
lipocalin protein
lipocalin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0504767.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Priority to GBGB0504767.5A priority Critical patent/GB0504767D0/en
Publication of GB0504767D0 publication Critical patent/GB0504767D0/en
Priority to EP06710035A priority patent/EP1869074A1/en
Priority to BRPI0609020A priority patent/BRPI0609020A2/pt
Priority to MX2007010809A priority patent/MX2007010809A/es
Priority to US11/817,296 priority patent/US20080254035A1/en
Priority to PCT/GB2006/000820 priority patent/WO2006095164A1/en
Priority to AU2006221859A priority patent/AU2006221859B2/en
Priority to CA002599540A priority patent/CA2599540A1/en
Priority to CNA2006800153195A priority patent/CN101189257A/zh
Priority to KR1020077022395A priority patent/KR20070118614A/ko
Priority to EA200701918A priority patent/EA011816B1/ru
Priority to JP2008500259A priority patent/JP4933527B2/ja
Priority to UAA200711037A priority patent/UA94221C2/ru
Priority to IL185547A priority patent/IL185547A0/en
Priority to NO20075068A priority patent/NO20075068L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
GBGB0504767.5A 2005-03-08 2005-03-08 Lipocalin protein Ceased GB0504767D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0504767.5A GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein
JP2008500259A JP4933527B2 (ja) 2005-03-08 2006-03-08 リポカリンタンパク質
AU2006221859A AU2006221859B2 (en) 2005-03-08 2006-03-08 Lipocalin protein
CNA2006800153195A CN101189257A (zh) 2005-03-08 2006-03-08 脂质运载蛋白
MX2007010809A MX2007010809A (es) 2005-03-08 2006-03-08 Proteina lipocalina.
US11/817,296 US20080254035A1 (en) 2005-03-08 2006-03-08 Lipocalin Protein
PCT/GB2006/000820 WO2006095164A1 (en) 2005-03-08 2006-03-08 Lipocalin protein
EP06710035A EP1869074A1 (en) 2005-03-08 2006-03-08 Lipocalin protein
CA002599540A CA2599540A1 (en) 2005-03-08 2006-03-08 Lipocalin protein
BRPI0609020A BRPI0609020A2 (pt) 2005-03-08 2006-03-08 polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos"
KR1020077022395A KR20070118614A (ko) 2005-03-08 2006-03-08 리포칼린 단백질
EA200701918A EA011816B1 (ru) 2005-03-08 2006-03-08 Белок липокалин
UAA200711037A UA94221C2 (en) 2005-03-08 2006-08-03 Lipocalin protein
IL185547A IL185547A0 (en) 2005-03-08 2007-08-27 Lipocalin protein
NO20075068A NO20075068L (no) 2005-03-08 2007-10-08 Lipocalinprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504767.5A GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein

Publications (1)

Publication Number Publication Date
GB0504767D0 true GB0504767D0 (en) 2005-04-13

Family

ID=34452020

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0504767.5A Ceased GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein

Country Status (15)

Country Link
US (1) US20080254035A1 (enExample)
EP (1) EP1869074A1 (enExample)
JP (1) JP4933527B2 (enExample)
KR (1) KR20070118614A (enExample)
CN (1) CN101189257A (enExample)
AU (1) AU2006221859B2 (enExample)
BR (1) BRPI0609020A2 (enExample)
CA (1) CA2599540A1 (enExample)
EA (1) EA011816B1 (enExample)
GB (1) GB0504767D0 (enExample)
IL (1) IL185547A0 (enExample)
MX (1) MX2007010809A (enExample)
NO (1) NO20075068L (enExample)
UA (1) UA94221C2 (enExample)
WO (1) WO2006095164A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
HRP20180045T1 (hr) 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN104487587A (zh) 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
JP6985934B2 (ja) 2015-04-29 2021-12-22 フレッド ハッチンソン キャンサー リサーチ センター 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
AU2017250295B2 (en) 2016-04-14 2022-08-25 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3595706A1 (en) 2017-03-17 2020-01-22 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3723787A4 (en) 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US12398402B2 (en) 2018-09-12 2025-08-26 Fred Hutchinson Cancer Center Reducing CD33 expression to selectively protect therapeutic cells
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
US12043667B2 (en) 2019-05-04 2024-07-23 Inhibrx Biosciences, Inc. CLEC12a binding polypeptides and uses thereof
CA3148027A1 (en) 2019-05-08 2020-11-12 2Seventy Bio, Inc. Cll-1 targeted immunotherapies
US20220257796A1 (en) 2019-07-02 2022-08-18 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
CA3181963A1 (en) 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
CN111979249B (zh) * 2020-07-28 2021-12-10 复旦大学附属眼耳鼻喉科医院 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) * 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5362865A (en) * 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) * 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2001285183A1 (en) * 2000-08-31 2002-03-13 Zymogenetics Inc. Human phermone polypeptides

Also Published As

Publication number Publication date
UA94221C2 (en) 2011-04-26
BRPI0609020A2 (pt) 2016-11-29
EP1869074A1 (en) 2007-12-26
MX2007010809A (es) 2007-11-07
EA011816B1 (ru) 2009-06-30
JP2008536483A (ja) 2008-09-11
AU2006221859B2 (en) 2011-09-22
KR20070118614A (ko) 2007-12-17
US20080254035A1 (en) 2008-10-16
IL185547A0 (en) 2008-01-06
NO20075068L (no) 2007-12-10
AU2006221859A1 (en) 2006-09-14
EA200701918A1 (ru) 2008-02-28
CN101189257A (zh) 2008-05-28
JP4933527B2 (ja) 2012-05-16
CA2599540A1 (en) 2006-09-14
WO2006095164A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
IL185547A0 (en) Lipocalin protein
GB0507537D0 (en) Protein resistant surfaces
GB0422901D0 (en) Lipocalin protein
GB0514482D0 (en) Protein
GB0511861D0 (en) Proteins
GB0522113D0 (en) vWFA-domain containing proteins
GB0504075D0 (en) Plac-1-like protein
GB0513690D0 (en) Protein
GB0508160D0 (en) Protein
GB0514718D0 (en) Protein
GB0514789D0 (en) Protein
GB0512426D0 (en) Protein
GB0515180D0 (en) Protein
GB0516302D0 (en) Protein
GB0515438D0 (en) Protein
GB0513561D0 (en) Protein
GB0514717D0 (en) Protein
GB0515436D0 (en) Protein
GB0515443D0 (en) Protein
GB0401882D0 (en) Protein
GB0404929D0 (en) Protein
GB0514788D0 (en) Proteins
GB0514481D0 (en) Proteins
GB0513505D0 (en) Proteins
GB0504766D0 (en) Metalloprotease protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)